Claritev Corporation Reports First Quarter 2026 Results
Key Terms
adjusted ebitda financial
free cash flow financial
-
Q1 2026 Revenues of
$244.7 million 5.8% compared to Q1 2025 -
Net Loss of
$73.6 million -
Adjusted EBITDA of
$146.9 million 3.4% compared to Q1 2025
(Adjusted EBITDA Margin of60.0% versus61.4% in Q1 2025)
“Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence — confidence in our team, confidence in our growth, and confidence in the durability of the foundation we are building,” said Travis Dalton, Chairman, CEO and President of Claritev.
Mr. Dalton added, “At our Investor Day in March, we laid out the path and key drivers behind Vision 2030. Simply put, we are matching our horizontal products with an expanding vertical market strategy that serves the entire healthcare lifecycle. It’s working and our first quarter performance underscores how the combination of that vision and our competitive position is leading to greater success and faster growth. We will continue to press that competitive advantage — one that is grounded in our long-standing trusted client relationships, scaled data ecosystem, deep domain expertise, and increasingly, our differentiated application of AI to accelerate progress.”
Doug Garis, Claritev Chief Financial Officer, commented, “Our first quarter results demonstrate the consistency and quality of Claritev’s core, and the growth opportunities created by our expansion into new markets and verticals. Our revenue and Adjusted EBITDA outperformance were driven by that consistency in our business, and the favorable market trends that helped drive our return to top line growth in 2025. Notably, the strong Q1 bookings performance comes from our core offerings and markets, alongside significant wins in the provider and government verticals, demonstrating the diversification of Claritev’s revenue streams and the foundation we are building to deliver sustainable, long term growth.”
Business and Financial Highlights
-
Revenues of
$244.7 million 5.8% , compared to revenues of$231.3 million
-
Net loss of
$73.6 million $71.3 million
-
Adjusted EBITDA of
$146.9 million 3.4% , compared to Adjusted EBITDA of$142.1 million
-
Net cash used in operating activities of
$45.8 million $30.1 million
-
Free Cash Flow of
$(92.5) million $(68.9) million
-
The Company ended Q1 2026 with
$21.3 million
2026 Financial Guidance1
The Company is updating its full-year 2026 guidance, detailed in the table below:
Financial Metric |
|
Prior FY 2026 Guidance |
|
Updated FY 2026 Guidance |
|
|
(as of 2/23/2026) |
|
(as of 5/7/2026) |
Revenues |
|
|
|
|
Adjusted EBITDA1 |
|
|
|
|
Capital expenditures |
|
|
|
|
Effective tax rate |
|
|
|
|
Free Cash Flow |
|
|
|
|
Conference Call Information
The Company will host a conference call today, Thursday, May 7, 2026 at 8:00 a.m.
Participants wishing to join the operator assisted call can dial 646-968-2525 and reference Conference ID 2181839.
A replay of the conference call will be available after the call through the webcast archived on the Investor Relations section of the Company’s website.
About Claritev
Claritev is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality across the
| _________________ |
1 We have not reconciled the forward-looking Adjusted EBITDA guidance included above to the most directly comparable GAAP (as defined below) measure because this cannot be done without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation (including stock-based compensation), transaction-related expenses, and certain fair value measurements, which are potential adjustments to future earnings. We expect the variability of these items to have a potentially unpredictable, and a potentially significant, impact on our future GAAP financial results. |
Forward Looking Statements
This press release contains forward-looking statements regarding our opinions, beliefs, projections, business plans and expectations. These forward-looking statements may differ materially from actual results due to a variety of factors and can generally be identified by the use of forward-looking terminology, including the terms “believes,” “estimates,” “anticipates,” “expects,” “seeks,” “projects,” “forecasts,” “intends,” “plans,” “may,” “will” or “should” or, in each case, their negative or other variations or comparable terminology. These statements include all matters that are not historical facts. They appear in a number of places throughout this press release, including, but not limited to, statements relating to our ability to deliver anticipated results; our ability to successfully implement our transformation plan; the anticipated growth of our business, including our expansion into new markets; our expectations regarding future revenue streams; our 2026 outlook and guidance; and the long-term prospects of the Company. Such forward-looking statements are based on available current market information and management’s expectations, beliefs and forecasts concerning future events impacting the business. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that these forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These factors include: loss of, or a significant reduction in the work we do for, our clients, particularly our largest clients; the ability to achieve the goals of our strategic plans and recognize the anticipated strategic, operational, growth and efficiency benefits when expected; our ability to enter new lines of business and broaden the scope of our solutions; trends in the
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on our business. There can be no assurance that future developments affecting our business will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, and other documents filed or to be filed with the SEC by us. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.
We undertake no obligation to update these statements as a result of new information or future events or otherwise, except as may be required under applicable securities laws.
Non-GAAP Financial Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles in
EBITDA, Adjusted EBITDA, free cash flow, unlevered free cash flow and adjusted cash conversion ratio are supplemental measures of Claritev’s performance that are not required by or presented in accordance with GAAP. These measures are not measurements of our financial or operating performance under GAAP, have limitations as analytical tools and should not be considered in isolation or as an alternative to net (loss) income, cash flows or any other measures of performance prepared in accordance with GAAP.
EBITDA represents net (loss) income before interest expense, interest income, income tax provision (benefit), depreciation, amortization of intangible assets, and non-income taxes. Adjusted EBITDA is EBITDA as further adjusted by certain items as described in the table below.
In addition, in evaluating EBITDA and Adjusted EBITDA you should be aware that in the future, we may incur expenses similar to the adjustments in the presentation of EBITDA and Adjusted EBITDA. The presentation of EBITDA and Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. The calculations of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Based on our industry and debt financing experience, we believe that EBITDA and Adjusted EBITDA are customarily used by investors, analysts and other interested parties to provide useful information regarding a company’s ability to service and/or incur indebtedness.
We also believe that Adjusted EBITDA is useful to investors and analysts in assessing our operating performance during the periods these charges were incurred on a consistent basis with the periods during which these charges were not incurred. Both EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider either in isolation, or as a substitute for analysis of our results as reported under GAAP. Some of the limitations are:
- EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, our working capital needs;
- EBITDA and Adjusted EBITDA do not reflect interest expense, or the cash requirements necessary to service interest or principal payments on our debt;
- EBITDA and Adjusted EBITDA do not reflect our tax expense or the cash requirements to pay our taxes; and
- Although depreciation and amortization are non-cash charges, the tangible assets being depreciated will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements.
Claritev’s presentation of Adjusted EBITDA should not be construed as an inference that our future results and financial position will be unaffected by unusual items.
Free cash flow is defined as net cash provided by operating activities less capital expenditures, all as disclosed in the Consolidated Statements of Cash Flows. Unlevered free cash flow is defined as net cash provided by operating activities less capital expenditures, plus cash interest paid, all as disclosed in the condensed consolidated statements of cash flows. Free cash flow and unlevered free cash Flow are measures of our operational performance used by management to evaluate our business after purchases of property and equipment and, in the case of unlevered free cash flow, prior to the impact of our capital structure. Free cash flow and unlevered free cash Flow should be considered in addition to, rather than as a substitute for, consolidated net income as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. Additionally, Claritev’s definitions of free cash flow and unlevered free cash flow are limited, in that they do not represent residual cash flows available for discretionary expenditures, due to the fact that the measures do not deduct the payments required for debt service, in the case of unlevered free cash flow, and other contractual obligations or payments made for business acquisitions.
Adjusted cash conversion ratio is defined as unlevered free cash flow divided by Adjusted EBITDA. Claritev believes that the presentation of the adjusted cash conversion ratio provides useful information to investors because it is an financial performance measure that shows how much of its Adjusted EBITDA Claritev converts into unlevered free cash flow.
CLARITEV CORPORATION |
|||||||
Condensed Consolidated Balance Sheets (Unaudited) |
|||||||
(in thousands, except share and per share data) |
|||||||
|
March 31, 2026 |
|
December 31, 2025 |
||||
Assets |
|
|
|
||||
Current assets: |
|
|
|
||||
Cash and cash equivalents |
$ |
21,327 |
|
|
$ |
16,814 |
|
Restricted cash |
|
13,401 |
|
|
|
11,527 |
|
Trade accounts receivable, net |
|
140,917 |
|
|
|
127,615 |
|
Prepaid expenses |
|
35,349 |
|
|
|
31,992 |
|
Prepaid taxes |
|
4,101 |
|
|
|
11,526 |
|
Unbilled Independent Dispute Resolution fees, net |
|
13,304 |
|
|
|
10,563 |
|
Other current assets, net |
|
13,868 |
|
|
|
14,330 |
|
Total current assets |
|
242,267 |
|
|
|
224,367 |
|
Property and equipment, net |
|
343,599 |
|
|
|
326,326 |
|
Operating lease right-of-use assets |
|
13,549 |
|
|
|
13,966 |
|
Goodwill |
|
2,405,853 |
|
|
|
2,405,853 |
|
Other intangibles, net |
|
1,798,696 |
|
|
|
1,884,604 |
|
Other assets, net |
|
35,335 |
|
|
|
33,342 |
|
Total assets |
$ |
4,839,299 |
|
|
$ |
4,888,458 |
|
Liabilities and Shareholders’ Deficit |
|
|
|
||||
Current liabilities: |
|
|
|
||||
Accounts payable |
$ |
59,176 |
|
|
$ |
60,463 |
|
Accrued interest |
|
52,277 |
|
|
|
100,009 |
|
Operating lease obligation, short-term |
|
4,907 |
|
|
|
4,705 |
|
Current portion of long-term debt |
|
14,690 |
|
|
|
14,690 |
|
Accrued compensation |
|
19,672 |
|
|
|
45,238 |
|
Other accrued expenses |
|
38,842 |
|
|
|
36,253 |
|
Total current liabilities |
|
189,564 |
|
|
|
261,358 |
|
Long-term debt |
|
4,574,253 |
|
|
|
4,560,440 |
|
2025 Revolving Credit Facility |
|
125,000 |
|
|
|
20,000 |
|
Operating lease obligation, long-term |
|
15,060 |
|
|
|
16,236 |
|
Deferred income taxes |
|
169,836 |
|
|
|
197,599 |
|
Total liabilities |
|
5,073,713 |
|
|
|
5,055,633 |
|
Commitments and contingencies (Note 7) |
|
|
|
||||
Shareholders’ deficit: |
|
|
|
||||
Shareholder interests |
|
|
|
||||
Preferred stock, |
|
— |
|
|
|
— |
|
Class A Common stock, |
|
2 |
|
|
|
2 |
|
Additional paid-in capital |
|
2,402,923 |
|
|
|
2,398,423 |
|
Accumulated deficit |
|
(2,502,980 |
) |
|
|
(2,429,420 |
) |
Accumulated other comprehensive loss |
|
(2,351 |
) |
|
|
(4,172 |
) |
Treasury stock - 742,859 shares as of March 31, 2026 and December 31, 2025 |
|
(138,733 |
) |
|
|
(138,733 |
) |
Total shareholders’ (deficit)/equity attributable to Claritev Corporation |
|
(241,139 |
) |
|
|
(173,900 |
) |
Non-controlling interests |
|
6,725 |
|
|
|
6,725 |
|
Total shareholders' deficit |
|
(234,414 |
) |
|
|
(167,175 |
) |
Total liabilities and shareholders’ deficit |
$ |
4,839,299 |
|
|
$ |
4,888,458 |
|
CLARITEV CORPORATION |
|||||||
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) |
|||||||
(in thousands, except share and per share data) |
|||||||
|
Three Months Ended March 31, |
||||||
|
2026 |
|
2025 |
||||
Revenues |
$ |
244,678 |
|
|
$ |
231,330 |
|
Costs of services (exclusive of depreciation and amortization of intangible assets shown below) |
|
69,080 |
|
|
|
60,436 |
|
General and administrative expenses |
|
57,830 |
|
|
|
46,968 |
|
Depreciation |
|
25,183 |
|
|
|
24,546 |
|
Amortization of intangible assets |
|
85,908 |
|
|
|
85,971 |
|
Loss on disposal of leases |
|
38 |
|
|
|
3,317 |
|
Loss on sale of assets |
|
— |
|
|
|
350 |
|
Total expenses |
|
238,039 |
|
|
|
221,588 |
|
Operating income |
|
6,639 |
|
|
|
9,742 |
|
Interest expense |
|
99,542 |
|
|
|
91,636 |
|
Interest income |
|
(182 |
) |
|
|
(488 |
) |
Transaction costs related to refinancing transaction |
|
— |
|
|
|
7,792 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
670 |
|
Net loss before taxes |
|
(92,721 |
) |
|
|
(89,868 |
) |
Benefit for income taxes |
|
(19,161 |
) |
|
|
(18,549 |
) |
Net loss |
|
(73,560 |
) |
|
|
(71,319 |
) |
Less: net loss attributable to non-controlling interests |
|
— |
|
|
|
— |
|
Net loss attributable to Claritev Corporation |
$ |
(73,560 |
) |
|
$ |
(71,319 |
) |
|
|
|
|
||||
Weighted average shares outstanding – Basic and Diluted |
|
16,692,340 |
|
|
|
16,273,439 |
|
|
|
|
|
||||
Net loss per share – Basic and Diluted |
$ |
(4.41 |
) |
|
$ |
(4.38 |
) |
|
|
|
|
||||
Net loss attributable to Claritev Corporation |
|
(73,560 |
) |
|
|
(71,319 |
) |
Other comprehensive income (loss) |
|
|
|
||||
Change in unrealized gain (loss) on interest rate swaps, net of tax |
|
1,821 |
|
|
|
(1,624 |
) |
Comprehensive loss |
$ |
(71,739 |
) |
|
$ |
(72,943 |
) |
CLARITEV CORPORATION |
|||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) |
|||||||
(in thousands) |
|||||||
|
Three Months Ended March 31, |
||||||
|
2026 |
|
2025 |
||||
Operating activities: |
|
|
|
||||
Net loss |
$ |
(73,560 |
) |
|
$ |
(71,319 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
||||
Depreciation |
|
25,183 |
|
|
|
24,546 |
|
Amortization of intangible assets |
|
85,908 |
|
|
|
85,971 |
|
Amortization of the right-of-use asset |
|
556 |
|
|
|
1,022 |
|
Stock-based compensation |
|
6,895 |
|
|
|
6,329 |
|
Deferred income taxes |
|
(28,337 |
) |
|
|
(52,820 |
) |
Amortization of debt discounts and issuance costs |
|
1,554 |
|
|
|
712 |
|
Non-cash interest expense |
|
15,952 |
|
|
|
10,907 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
670 |
|
Loss on disposal of property and equipment |
|
— |
|
|
|
350 |
|
Loss on disposal of leases |
|
38 |
|
|
|
3,317 |
|
Changes in assets and liabilities: |
|
|
|
||||
Trade accounts receivable, net |
|
(16,043 |
) |
|
|
(3,708 |
) |
Prepaid taxes |
|
7,425 |
|
|
|
6,747 |
|
Prepaid expenses, other current and non-current assets |
|
600 |
|
|
|
(4,912 |
) |
Accounts payable |
|
(1,287 |
) |
|
|
(51,821 |
) |
Other accrued expenses, accrued interest and accrued liabilities |
|
(69,512 |
) |
|
|
15,074 |
|
Operating leases, net |
|
(1,151 |
) |
|
|
(1,121 |
) |
Net cash used in operating activities |
|
(45,779 |
) |
|
|
(30,056 |
) |
Investing activities: |
|
|
|
||||
Purchases of property and equipment |
|
(46,767 |
) |
|
|
(38,866 |
) |
Net cash used in investing activities |
|
(46,767 |
) |
|
|
(38,866 |
) |
Financing activities: |
|
|
|
||||
Repayments of Term Loan |
|
(3,672 |
) |
|
|
— |
|
Taxes paid on settlement of vested share awards |
|
(2,859 |
) |
|
|
(2,884 |
) |
Borrowings on 2025 Revolving Credit Facility |
|
145,000 |
|
|
|
130,000 |
|
Repayment of 2025 Revolving Credit Facility |
|
(40,000 |
) |
|
|
(50,000 |
) |
Payment of debt issuance costs |
|
— |
|
|
|
(4,267 |
) |
Proceeds from issuance of common stock under ESPP |
|
464 |
|
|
|
301 |
|
Net cash provided by financing activities |
|
98,933 |
|
|
|
73,150 |
|
Net increase in cash, cash equivalents and restricted cash |
|
6,387 |
|
|
|
4,228 |
|
Cash, cash equivalents and restricted cash at beginning of period |
|
28,341 |
|
|
|
29,672 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
34,728 |
|
|
$ |
33,900 |
|
|
|
|
|
||||
Cash and cash equivalents |
$ |
21,327 |
|
|
$ |
23,129 |
|
Restricted cash |
|
13,401 |
|
|
|
10,771 |
|
Cash, cash equivalents and restricted cash at end of period |
$ |
34,728 |
|
|
$ |
33,900 |
|
|
|
|
|
||||
Noncash investing and financing activities: |
|
|
|
||||
Purchases of property and equipment not yet paid |
$ |
17,046 |
|
|
$ |
9,694 |
|
Operating lease right-of-use assets obtained in exchange for operating lease liabilities |
$ |
— |
|
|
$ |
(10,411 |
) |
Supplemental disclosure of cash flow information: |
|
|
|
||||
Cash paid during the period for: |
|
|
|
||||
Interest |
$ |
(129,311 |
) |
|
$ |
(82,003 |
) |
Income taxes, net of refunds |
$ |
(1,636 |
) |
|
$ |
(2,532 |
) |
CLARITEV CORPORATION |
|||||||
Calculation of EBITDA and Adjusted EBITDA |
|||||||
(in thousands) |
|||||||
|
Three Months Ended March 31, |
||||||
|
2026 |
|
2025 |
||||
Net loss |
$ |
(73,560 |
) |
|
$ |
(71,319 |
) |
Adjustments: |
|
|
|
||||
Interest expense |
|
99,542 |
|
|
|
91,636 |
|
Interest income |
|
(182 |
) |
|
|
(488 |
) |
Benefit for income tax |
|
(19,161 |
) |
|
|
(18,549 |
) |
Depreciation |
|
25,183 |
|
|
|
24,546 |
|
Amortization of intangible assets |
|
85,908 |
|
|
|
85,971 |
|
Non-income taxes |
|
— |
|
|
|
553 |
|
EBITDA |
$ |
117,730 |
|
|
$ |
112,350 |
|
Adjustments: |
|
|
|
||||
Other expenses, net(1) |
|
11,528 |
|
|
|
2,764 |
|
Loss on sale of assets, including right-of-use assets |
|
38 |
|
|
|
3,667 |
|
Transformation costs(2) |
|
11,790 |
|
|
|
7,728 |
|
Integration expenses |
|
— |
|
|
|
380 |
|
Transaction costs related to refinancing transaction |
|
— |
|
|
|
7,792 |
|
Loss on extinguishment of debt |
|
— |
|
|
|
670 |
|
Stock-based compensation, including cRSUs |
|
5,828 |
|
|
|
6,718 |
|
Adjusted EBITDA |
$ |
146,914 |
|
|
$ |
142,069 |
|
(1) |
"Other expenses, net" represents impairment of other assets, non-integration related severance costs, legal expenses associated with the antitrust matters, start-up costs related to international expansion and miscellaneous non-recurring expenses. |
|
(2) |
"Transformation costs" represent costs directly associated with our multi-year transformation program called Vision 2030 which includes internal personnel costs for employees that have been either hired or redeployed and are fully dedicated to transformation activities, as well as other non-recurring and duplicative costs. At such time that internal personnel are redeployed to non-transformation activities, they will no longer be included as an adjustment herein. |
CLARITEV CORPORATION |
|||||||
Calculation of Unlevered Free Cash Flow and Adjusted Cash Conversion Ratio |
|||||||
(in thousands) |
|||||||
|
Three Months Ended March 31, |
||||||
|
2026 |
|
2025 |
||||
Net cash used in operating activities |
$ |
(45,779 |
) |
|
$ |
(30,056 |
) |
Purchases of property and equipment |
|
(46,767 |
) |
|
|
(38,866 |
) |
Free cash flow |
|
(92,546 |
) |
|
|
(68,922 |
) |
Interest paid |
|
129,311 |
|
|
|
82,003 |
|
Unlevered free cash flow |
$ |
36,765 |
|
|
$ |
13,081 |
|
|
|
|
|
||||
Adjusted EBITDA |
$ |
146,914 |
|
|
$ |
142,069 |
|
Adjusted cash conversion ratio |
|
25 |
% |
|
|
9 |
% |
|
|
|
|
||||
Net cash used in investing activities |
$ |
(46,767 |
) |
|
$ |
(38,866 |
) |
Net cash provided by financing activities |
$ |
98,933 |
|
|
$ |
73,150 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20260507038291/en/
Investor Relations Contact
Todd Friedman
VP, Investor Relations
Claritev
investor@claritev.com
Media Relations Contact
Jen O’Connor
VP, Brand Marketing
Claritev
press@claritev.com
Source: Claritev Corporation